AUTH:"San-Miguel J" - Search results

Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.

Zabaleta A, Puig N, Cedena MT, Oliver-Caldes A, Perez JJ, Moreno C, Tamariz-Amador LE, Rodriguez-Otero P, Prosper F, Gonzalez-Calle V, López-Corral L, Rey-Búa B, Puertas B, Mirás F, Sánchez-Pina JM, López-Muñoz N, Juan M, González-Navarro EA, Urbano Á, [...] Paiva B

Am J Hematol, 16 Nov 2024

Cited by: 0 articles | PMID: 39548827

Add to export list

30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis.

Ocio EM, Perrot A, Moreau P, Mateos MV, Bringhen S, Martínez-López J, Karlin L, Wang SY, Oprea C, Li Y, Kodas E, San-Miguel J

Hemasphere, 8(11):e70041, 05 Nov 2024

Cited by: 0 articles | PMID: 39507853 | PMCID: PMC11538320

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.

Martín-Sánchez E, Tamariz-Amador LE, Guerrero C, Zherniakova A, Zabaleta A, Maia C, Blanco L, Alignani D, Fortuño MA, Grande C, Manubens A, Arguiñano JM, Gomez C, Perez-Persona E, Olazabal I, Oiartzabal I, Panizo C, Prosper F, San-Miguel JF, [...] Asociación Vasco-Navarra de Hematología y Hemoterapia (ASOVASNA) cooperative group

Blood Cancer J, 14(1):111, 10 Jul 2024

Cited by: 0 articles | PMID: 38987557 | PMCID: PMC11237013

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma.

Palacios-Berraquero ML, Rodriguez-Marquez P, Calleja-Cervantes ME, Berastegui N, Zabaleta A, Burgos L, Alignani D, San Martin-Uriz P, Vilas-Zornoza A, Rodriguez-Diaz S, Inoges S, Lopez-Diaz de Cerio A, Huerga S, Tamariz E, Rifon J, Alfonso-Pierola A, Lasarte JJ, Paiva B, Hernaez M, [...] Prosper F

Blood Adv, 8(21):5479-5492, 01 Nov 2024

Cited by: 0 articles | PMID: 39058976 | PMCID: PMC11532743

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.

Lakhwani S, Mateos MV, Martínez-López J, Paiva B, Rosiñol Dachs L, Martínez R, Oriol A, Bargay J, González-Montes Y, Gironella M, Encinas C, Martín J, Jarque I, Granell M, Abella E, García-Mateo A, Hernández-Rivas JÁ, Ramila E, Krsnik I, [...] Hernández MT

Ann Hematol, 23 Oct 2024

Cited by: 0 articles | PMID: 39438321

Add to export list

An automated network-based tool to search for metabolic vulnerabilities in cancer.

Valcárcel LV, San José-Enériz E, Ordoñez R, Apaolaza I, Olaverri-Mendizabal D, Barrena N, Valcárcel A, Garate L, San Miguel J, Pineda-Lucena A, Agirre X, Prósper F, Planes FJ

Nat Commun, 15(1):8685, 11 Oct 2024

Cited by: 1 article | PMID: 39394196 | PMCID: PMC11470099

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.

Lasa M, Notarfranchi L, Agullo C, Gonzalez C, Castro S, Perez JJ, Burgos L, Guerrero C, Calasanz MJ, Flores-Montero J, Oriol A, Bargay J, Rios R, Cabañas V, Cabrera C, Martinez-Martinez R, Encinas C, De Arriba F, Hernandez MT, [...] PETHEMA/GEM Cooperative Group

J Clin Oncol, JCO2400635, 01 Oct 2024

Cited by: 0 articles | PMID: 39353166

Add to export list

A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies.

Zabaleta A, Blanco L, Kim PS, Bisht K, Wang H, Van de Velde H, Lasa M, Tamariz-Amador LE, Rodriguez-Otero P, San-Miguel J, Paiva B, Martín-Sánchez E

Br J Haematol, 22 Sep 2024

Cited by: 0 articles | PMID: 39308023

Add to export list

Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma.

Puig N, Agullo Roca C, Sanfeliciano TC, Cedena MT, Martínez-López J, Oriol A, Blanchard MJ, Ríos-Tamayo R, Iñigo Rodríguez B, Sureda A, Lakhwani S, de la Rubia Comos J, Gonzalez-Calle V, Cabañas V, Palomera L, Moraleda JMM, Bargay J, Castro S, Rosiñol L, [...] Mateos MV

Blood, blood.2024024995, 18 Sep 2024

Cited by: 0 articles | PMID: 39293025

Add to export list

Immunoparesis Recovery in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients, an Independent Prognostic Factor That Complements Minimal Residual Disease

Lakhwani S, Mateos MV, Martínez-López J, Paiva B, Dachs LR, Martínez R, Oriol A, Bargay J, González-Montes Y, Gironella M, Encinas C, Martín J, Jarque I, Granell M, Abella E, Mateo AG, Hernández-Rivas JÁ, Ramila E, Krsnik I, [...] Hernández M

Research Square, 02 Sep 2024

Cited by: 0 articles | PPR: PPR904618

Add to export list Preprint v1

Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.

San-Miguel J, Dhakal B, Patel N, Schecter JM, Lendvai N, Einsele H

Future Oncol, 20(33):2509-2520, 07 Aug 2024

Cited by: 1 article | PMID: 39110421 | PMCID: PMC11537292

Add to export list Review

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.

Martín-Sánchez E, Blanco L, Kim PS, Bisht K, Wang H, Van de Velde H, Jelinek T, Simoes C, Prosper F, San Miguel JF, Alfonso A, Bergua J, Rodríguez-Veiga R, Vives S, Martínez-Cuadrón D, Montesinos P, Paiva B, Zabaleta A

Blood Adv, 8(15):3875-3879, 01 Aug 2024

Cited by: 0 articles | PMID: 38815228 | PMCID: PMC11321322

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

Mateos MV, Martínez-López J, Rodriguez Otero P, González-Calle V, Gonzalez MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Alvarez Rivas MA, Bargay J, Gonzalez-Rodriguez AP, Alegre A, Escalante F, Iñigo Rodríguez MB, De La Rubia J, Teruel AI, de Arriba F, Palomera L, [...] Spanish Myeloma Group (GEM-Pethema)

J Clin Oncol, 42(27):3247-3256, 22 Jul 2024

Cited by: 1 article | PMID: 39038268 | PMCID: PMC11404760

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model.

Sánchez-Moreno I, Lasarte-Cia A, Martín-Otal C, Casares N, Navarro F, Gorraiz M, Sarrión P, Hervas-Stubbs S, Jordana L, Rodriguez-Madoz JR, San Miguel J, Prosper F, Lasarte JJ, Lozano T

J Immunother Cancer, 12(7):e008572, 01 Jul 2024

Cited by: 0 articles | PMID: 38955421 | PMCID: PMC11218034

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study.

González-Calle V, Rodríguez-Otero P, Sureda A, De Arriba F, Reinoso M, Ribas P, González-Rodríguez AP, González Y, Oriol A, Martínez-López J, González MS, Hernández MT, Sirvent M, Cedena T, Puig N, Paiva B, Bladé J, Lahuerta JJ, San-Miguel JF, Mateos MV

Haematologica, 109(7):2219-2228, 01 Jul 2024

Cited by: 0 articles | PMID: 38356463

Add to export list

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Lakhwani S, Rosiñol L, Puig N, Pico-Picos MA, Medina-González L, Martínez-López J, Paiva B, Cedena MT, Oriol A, Ríos-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Moraleda JM, Carrillo-Cruz E, Sureda A, Krsnik I, González E, Casado LF, [...] Hernández MT

Haematologica, 109(6):1909-1917, 01 Jun 2024

Cited by: 1 article | PMID: 38031761 | PMCID: PMC11141681

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple Myeloma

Palacios-Berraquero ML, Rodriguez-Marquez P, Calleja-Cervantes ME, Berastegi N, Zabaleta A, Burgos L, Alignani D, San Martin-Uriz P, Vilas-Zornoza A, Rodriguez-Diaz S, Inoges S, Lopez-Diaz de Cerio A, Huerga S, Tamariz E, Rifón J, Alfonso-Pierola A, Lasarte JJ, Paiva B, Hernaez M, [...] Prosper F

medRxiv, 22 May 2024

Cited by: 0 articles | PPR: PPR856878

Add to export list Preprint

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.

Ghobrial IM, Gormley N, Kumar SK, Mateos MV, Bergsagel PL, Chesi M, Dhodapkar MV, Dispenzieri A, Fonseca R, Getz G, Kastritis E, Kristinsson SY, Martinez-Climent JA, Manier S, Marinac CR, Maura F, Morgan GJ, Davies FE, Nadeem O, [...] San Miguel JF

Blood Cancer Discov, 5(3):146-152, 01 May 2024

Cited by: 3 articles | PMID: 38441243 | PMCID: PMC11061588

Add to export list Review Free full text in Europe PMC

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosiñol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, [...] GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group

Blood Cancer J, 14(1):74, 29 Apr 2024

Cited by: 0 articles | PMID: 38684670 | PMCID: PMC11059156

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Transcriptional Remodeling of the Stromal and Endothelial Microenvironment in MGUS to Multiple Myeloma Progression

Cenzano I, Cócera M, Bantan A, Larrayoz M, Vilas-Zornoza A, San-Martin P, Aguirre-Ruiz P, Alignani D, Lopez A, Barrios MM, Agreda DQ, González IS, Ruiz J, Lagani V, Tegner J, Martín-Subero I, Agirre X, Paiva B, Rodriguez-Otero P, [...] Prosper F

bioRxiv, 25 Apr 2024

Cited by: 0 articles | PPR: PPR843196

Add to export list Preprint

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.

Raje NS, Cohen AD, Patel KK, van de Donk NWCJ, Richter J, San-Miguel J

Clin Lymphoma Myeloma Leuk, 24(6):350-357, 22 Mar 2024

Cited by: 0 articles | PMID: 38627181

Add to export list Review

Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.

Cardona-Benavides IJ, Misiewicz-Krzeminska I, Rojas EA, De Ramón C, Sanz-Solas A, Isidro I, Quwaider D, López-Guerrero AM, Cuadrado M, Calasanz MJ, Rosiñol L, Martínez-López J, San Miguel JF, Mateos MV, Corchete LA, Gutiérrez NC

Haematologica, 109(3):877-887, 01 Mar 2024

Cited by: 1 article | PMID: 37646661

Add to export list

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.

Guerrero C, Puig N, Cedena MT, Calasanz MJ, Gutierrez NC, Fernandez M, Oriol A, Ríos-Tamayo R, Hernandez MT, Martínez-Martínez R, Bargay J, de Arriba F, Palomera L, Gonzalez-Rodriguez AP, Gonzalez Perez MS, Orfao A, Mateos MV, Martinez-Lopez J, Rosiñol L, [...] Paiva B

Blood, 143(7):597-603, 01 Feb 2024

Cited by: 5 articles | PMID: 38048552

Add to export list

Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma.

Paiva B, Zherniakova A, Nuñez-Córdoba JM, Rodriguez-Otero P, Shi Q, Munshi NC, Durie BGM, San-Miguel J

Blood Adv, 8(1):219-223, 01 Jan 2024

Cited by: 2 articles | PMID: 37639322 | PMCID: PMC10805640

Add to export list

This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.

Free full text in Europe PMC

Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.

Martin TG, Moreau P, Usmani SZ, Garfall A, Mateos MV, San-Miguel JF, Oriol A, Nooka AK, Rosinol L, Chari A, Karlin L, Krishnan A, Bahlis N, Popat R, Besemer B, Martínez-López J, Delforge M, Trancucci D, Pei L, [...] van de Donk NWCJ

Clin Lymphoma Myeloma Leuk, 24(3):194-202, 14 Nov 2023

Cited by: 3 articles | PMID: 38052709

Add to export list

Search life-sciences literature (45,100,050 articles, preprints and more)

Search results

Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy.

30-Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis.

Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19.

Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma.

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.

An automated network-based tool to search for metabolic vulnerabilities in cancer.

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma.

A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies.

Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma.

Immunoparesis Recovery in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients, an Independent Prognostic Factor That Complements Minimal Residual Disease

Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.

Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia.

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

Tethered IL15-IL15Rα augments antitumor activity of CD19 CAR-T cells but displays long-term toxicity in an immunocompetent lymphoma mouse model.

Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, nonrandomized, multicenter GEM-SELIBORDARA study.

Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.

Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in Multiple Myeloma

Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Transcriptional Remodeling of the Stromal and Endothelial Microenvironment in MGUS to Multiple Myeloma Progression

Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.

Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.

Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma.

Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study.

Partnerships & funding